In the
biotech sector,
Revvity RVTY has been making significant headlines. The company has witnessed varied activities including stake adjustments and financial results announcements. Major firms such as
Sumitomo Mitsui Trust Group and
Mirae Asset Global Investments have increased their shares in Revvity. However,
abrdn plc and
Slocum Gordon & Co LLP decided to trim their positions. Revvity released its Q4 earnings and financial results for 2024, demonstrating significant
organic growth and surpassing predictions. The company has a consensus rating of
'Moderate Buy' amongst analysts and expects a strong price appreciation according to
KeyCorp and
Barclays. Revvity's partnership with
Element Biosciences promises to revolutionize neonatal genetic testing. There's concern about lower 2025 earnings despite a strong fourth quarter.
FDA approval has been granted for an automated testosterone test. However, there has also been insider selling activity from individuals like
Joel Goldberg and
Michelle Mcmurry-heath. The company is looking to redefine pharma collaboration with its software synergy solution, facing competitors and legal challenges. Their Scientific SaaS platform will accelerate drug and materials development.
Revvity RVTY News Analytics from Tue, 09 May 2023 07:00:00 GMT to Sat, 15 Feb 2025 06:08:29 GMT -
Rating 5
- Innovation 3
- Information 7
- Rumor 1
